Skip to main content
. Author manuscript; available in PMC: 2008 Dec 29.
Published in final edited form as: Toxicol Appl Pharmacol. 2007 Aug 7;225(2):206–213. doi: 10.1016/j.taap.2007.07.016

Fig. 3. tBHQ or SF pretreatment protects cells from As(III)- and MMA(III)-induced toxicity.

Fig. 3

(A and B) UROtsa cells were pretreated and co-treated with DMSO (diamond), tBHQ (triangle) or SF (square). Treatment conditions are: 40 μM (24 h) pretreatment and 5 μM (24h) cotreatment for tBHQ, 8 μM (24 h) pretreatment and 0.5 μM (24h) cotreatment for SF. During the cotreatment time period, 5 μM tBHQ or 0.5 μM SF was added along with the indicated concentrations of As(III) or MMA(III). (C–F) Cell viability assay was carried out in WT-MEF (C and D) and Nrf2−/− MEF cells (E and F). The pretreatment and cotreatment conditions for tBHQ or SF were same as described in Figure 3A or 3B.